Dr. Susan Slovin on 177Lu-PSMA-617 and the rise of radiopharmaceuticals in mCRPC

Susan F. Slovin, MD, PhD, medical oncologist, associate vice chair, Academic Administration, Department of Medicine, Memorial Sloan Kettering Cancer Center, discusses emergence of 177Lu-PSMA-617 (LuPSMA) and overall significance of radiopharmaceuticals inmetastatic castration-resistant prostate cancer (mCRPC)

Data from the phase 3 VISION trial presented at the 2021 ASCO Annual Meeting showed that adding LuPSMA to standard of care (SOC) led to a nearly 40% reduction in the risk of death versus SOC alone in patients with progressive PSMA-positive metastatic mCRPC.

Related Videos
Benjamin Lowentritt, MD, FACS, in an interview with Urology Times
Dr. Goldfischer in an interview during the LUGPA Annual Meeting
Related Content
© 2023 MJH Life Sciences

All rights reserved.